CD8A and metastatic melanoma: A more detailed analysis of immune response (CD4, CD8, Treg profile including activation/proliferation stage) both in blood and in tumor biopsies is planned to be re-investigated in the phase II trial in metastatic melanoma, in which NHS-IL2 is given with stereotactic body irradiation (clinicaltrial.gov identifier NCT01973608).